Effects of Quercetin on Cardiometabolic Outcomes

University of Central Lancashire

Status: Enrolling

Conditions: Cardiometabolic Syndrome

Treatments: Dietary Supplement: Quercetin; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT06230861

Quercetin cardiometabolic

Details and patient eligibility

About

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy
• Between 18 & 65 years
• Non-smoker
• BMI < 30
• Able to give informed consent

Exclusion criteria

• Pregnancy
• Diabetes or any other metabolic/ uncontrolled hypertensive conditions
• Food allergies to quercetin
• Habitual consumption of quercetin
• Not regularly taking medication or antioxidant supplements

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 2 patient groups, including a placebo group

Quercetin tablets 500mg 1 x pe

Experimental group

Description:

Quercetin tablets 500mg 1 x per day

Treatment:

Dietary Supplement: Quercetin

Placebo

Placebo Comparator group

Treatment:

Other: Placebo